Brief overview of Testolone (RAD140)

Testolone (RAD140) is one of the most potent SARMs available. It significantly promotes gains in muscle mass and strength, resulting in a hard, full, and highly vascularized appearance. While using it, many athletes report increased muscle stiffness and a constant feeling of “fullness.”

Compared to milder SARMs such as Ostarine or Andarine, supplementation with RAD140 causes a significantly greater suppression of endogenous testosterone. However, it has a highly valued characteristic: a protective effect on the prostate, making it useful even when combined with anabolic-androgenic steroids.
Experimental studies also indicate a potential positive effect in reducing breast cancer, making testolone a subject of clinical interest.

What is Testolone (RAD140)?

RAD140, also known as testolone, is a selective androgen receptor modulator developed by Radius Pharmaceuticals in the late 2000s. It was originally designed as a potential treatment for muscle loss (sarcopenia) and was subsequently studied in the context of breast cancer

From a pharmacological standpoint, RAD140 exhibits excellent anabolic properties, comparable to those of LGD-4033, with greater tissue selectivity. It acts as a partial agonist in prostate tissue, helping to reduce the risk of prostatic hyperplasia even in the presence of testosterone or its derivatives.

An additional benefit is the improvement in lipid profile ( LDL, HDL, and triglycerides) without a significant increase in liver enzymes in most users.

Scientific research on RAD140

RAD140 is an experimental SARM developed by Radius Health Inc. for androgen replacement therapy. In 2020, it was licensed to Ellipses Pharmaceuticals.
Preclinical animal studies have shown that testolone can increase lean muscle mass and bone density with a safety profile that is potentially superior to that of traditional testosterone.

The first clinical trial in humans began in 2017 and was completed in 2020, involving postmenopausal women with breast cancer.

Main effects of RAD140 (Testolone)

• Significant increase in muscle mass

• Marked increase in strength, often greater than muscle growth itself

• Reduction of body fat

• Increase in bone mineral density

• Protection of the prostate thanks to partial agonism on androgen receptors

• Activity on androgen receptors in breast cancer cells, with repression of the ESR1 gene

Effect on the liver

Anecdotal evidence and blood tests conducted on athletes suggest that RAD140 is not hepatotoxic in most cases. However, as a precaution, it is advisable to have blood tests (ALT, AST) performed before and after the cycle.
Only one case of liver dysfunction has been reported during a clinical trial, and the cause has not yet been fully clarified.

Lipid profile

Like all SARMs, testolone can also affect blood lipids, with a possible reduction in HDL and increase in LDL. It is recommended to monitor cholesterol during the cycle.

Testosterone suppression

Testosterone suppression with RAD140 typically occurs between the 6th and 7th week, especially at doses of ≥10 mg.
At higher doses (20–30 mg), suppression may occur earlier. To reduce this risk, many users do not exceed 10 mg per day

Half-life

• About 60 hours

RAD140 dosages

• Beginners: 5–10 mg per day

• Average dosage: 10–20 mg per day

• Maximum recommended dose: 30 mg per day

• Women: 5–10 mg per day